Eva Domingo Domènech, EHA 2019 – The Phase II CHECKMATE 205 Study
We are joined by Eva Domingo Domènech at EHA 2019 to discuss her presentation on nivolumab plus doxorubicin, vinblastine and dacarbazine for newly diagnosed advanced-stage classical Hodgkin lymphoma: 2-year extended follow-up from cohort D of the phase II CHECKMATE 205 study.
Questions
1. What are the major unmet needs in the treatment of advanced stage classical Hodgkin lymphoma? (0:05)
2. What is the rationale for treatment with nivolumab followed by nivolumab plus doxorubicin, vinblastine and dacarbazine? (0:56)
3. Could you tell us about the efficacy and safety findings you are presenting from Cohort D of the CHECKMATE 205 study? (1:49)
4. Which patients are most likely to benefit from this treatment regimen and in which patients is it contraindicated? (3:00)
5. Can patients who receive nivolumab go on to receive allogeneic HSCT? (4:15)
Eva Domingo Domènech has no conflicts of interest in relation to this video.
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
